X
CYTK icon

Xponance’s Cytokinetics CYTK Stock Holding History

Xponance’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.7M Buy
19,971
+2,935
+17% +$211K 0.01% 639
2026
Q1 		$1.12M Buy
17,036
+2,651
+18% +$168K 0.01% 710
2025
Q4 		$914K Sell
14,385
-2,328
-14% -$145K 0.01% 719
2025
Q3 		$919K Buy
16,713
+3
+0% +$124 0.01% 735
2025
Q2 		$552K Buy
16,710
+149
+0.9% +$5.18K ﹤0.01% 913
2025
Q1 		$666K Buy
16,561
+33
+0.2% +$1.52K 0.01% 844
2024
Q4 		$777K Buy
16,528
+853
+5% +$44.3K 0.01% 814
2024
Q3 		$828K Buy
15,675
+473
+3% +$26.4K 0.01% 767
2024
Q2 		$824K Buy
15,202
+1,348
+10% +$81.4K 0.01% 735
2024
Q1 		$971K Buy
13,854
+8,231
+146% +$637K 0.01% 730
2023
Q4 		$469K Buy
+5,623
New +$204K 0.01% 952
2023
Q1 		– Sell
-4,699
Closed -$215K – 1244
2022
Q4 		$215K Buy
4,699
+73
+2% +$3.14K ﹤0.01% 1110
2022
Q3 		$224K Buy
+4,626
New +$223K ﹤0.01% 1064

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Xponance's CYTK Position: Q2 2026 in Review

Xponance increased its Cytokinetics (CYTK) stake by 17% in Q2 2026, buying an estimated $211K and bringing the position to 19,971 shares worth $1.7M. The position accounts for 0.01% of the portfolio, ranked #639.

Xponance first reported a position in CYTK in Q3 2022 and has held it in 13 quarters since. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • Xponance held 19,971 shares of Cytokinetics worth $1.7M as of Q2 2026.
  • Xponance bought 2,935 Cytokinetics shares in Q2 2026, an estimated $211K.
  • Cytokinetics made up 0.01% of Xponance's portfolio in Q2 2026, its #639 holding.
  • Xponance first reported a position in Cytokinetics in Q3 2022 and has held it in 13 quarters since.
  • 482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Xponance's 13F filing for Q2 2026, filed 10 Aug 2026.